title: Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables.
abstract: We have previously reported that the activity in platelets of the important antioxidant enzyme glutathione peroxidase (GPx) is inversely correlated with computed tomographic (CT) measures of brain atrophy in a population of patients with chronic schizophrenia, suggesting that low GPx may be a vulnerability factor in those schizophrenic patients with structural brain abnormalities. The significance of this finding has now been explored in a larger clinical population by examining the relation of GPx and CT parameters to psychosocial variables and to the activity of platelet monoamine oxidase (MAO), which has also been reported to be altered in certain schizophrenic populations. In the present study, low platelet GPx and high brain atrophy were found to be associated with DSM-III diagnoses of nonparanoid schizophrenia, a high degree of chronicity, and a predominance of negative symptoms. Contrary to some literature reports, atrophy also correlated with age and length of illness among the schizophrenic patients, although the contribution of these factors was less than that of low GPx, which was itself not age dependent. The ventricle-brain ratio (VBR) and atrophy were highly correlated in a control group of affective disorder patients, but not in the schizophrenic group, where large VBRs were found predominantly in the DSM-III undifferentiated subgroup. The low-GPx/high-atrophy schizophrenic patients had normal platelet MAO levels, and MAO was significantly lower only in the paranoid subgroup, consistent with reported observations. There was no evidence for a neuroleptic-induced effect on either enzyme.
authors.affiliation: Department of Neurology, Hahnemann University, Philadelphia, PA 19102-1192.
authors.forename: T D
authors.initials: TD
authors.lastname: Buckman
authors.forename: A
authors.initials: A
authors.lastname: Kling
authors.forename: M S
authors.initials: MS
authors.lastname: Sutphin
authors.forename: A
authors.initials: A
authors.lastname: Steinberg
authors.forename: S
authors.initials: S
authors.lastname: Eiduson
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001284:Atrophy; D001792:Blood Platelets / Q000201:enzymology*; D001921:Brain / Q000473:pathology*; D002552:Cerebral Ventricles / Q000473:pathology; D002908:Chronic Disease; D005500:Follow-Up Studies; D005979:Glutathione Peroxidase / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000097:blood*; D019965:Neurocognitive Disorders / Q000201:enzymology*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000201:enzymology*; D012563:Schizophrenia, Paranoid / Q000201:enzymology; D012565:Schizophrenic Psychology; D012917:Social Adjustment; D014057:Tomography, X-Ray Computed
chemical_list: D014150:Antipsychotic Agents; D005979:Glutathione Peroxidase; D008995:Monoamine Oxidase